미네랄-골대사질환과 만성콩팥병

●

만성콩팥병 3단계 이상의 환자(GFR < 60 mL/min/1.73 m

)에서는 정기적인 만성콩팥병 미네랄-골대사 질환 여부 모니터링이 필요하며 이를 위해 정기적인 칼슘, 인, 부갑상선호르몬(PTH), 알칼리인산분해효소 (ALP), 비타민 D 검사를 권고한다. 소아에서는 2단계부터 고려할 수 있다.

●

만성콩팥병 환자에서(3단계 이상) 골강도 감소 및 골절 위험도 모니터링을 위해 골밀도 검사 시행을 고려할 수 있고, 혈관 석회화 진행 정도를 모니터링하기 위해 복부 측면 X-ray의 촬영을 고려할 수 있다.

●

만성콩팥병 환자에서(3단계 이상) 혈중 인산수치는 정상 유지를 목표로 하며, 고인산혈증이 발생한 경우 인산

제한 식이를 포함한 치료를 고려할 수 있다.

참고문헌

1. 대한의학회·질병관리청. 일차 의료용 근거기반 당뇨병 권고 요약본. 2018.

2. 대한당뇨병학회. 2019 당뇨병 진료지침 제6판. 2019.

3. Diabetes Canada Clinical Practice Guidelines Expert Committee. Chronic kidney disease in diabetes. 2018.

4. Warram JH, Gearin G, Laffel L, et al. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 1996;7:930-937.

5. Mathiesen ER, Ronn B, Storm B, et al. The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study. Diabet Med 1995;12:482-487.

6. Lemley KV, Abdullah I, Myers BD, et al. Evolution of incipient nephropathy in type 2 diabetes mellitus. Kidney Int 2000;58:1228-1237.

7. Gall MA, Nielsen FS, Smidt UM, et al. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia 1993;36:1071-1078.

8. Jacobsen P, Rossing K, Tarnow L, et al. Progression of diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int Suppl 1999;71:S101-S105.

9. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes NICE clinical guideline. 2008.

10. NKF. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012;60(5):850-886.

11. American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes-2020. Diabetes Care 2020;43(1):S135–S151.

12. KDIGO. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. 2013.

13. JSN. Essential points from evidence-based clinical practice guidelines for chronic kidney disease 2018. 2019.

14. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive

50

normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-1097.

18. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998;351:1755-1762.

19. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001;345:851-860.

20. Lindholm L, Ibsen J, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-1010.

21. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342(3):145-153.

22. Brenner BM, Cooper ME, de Zeeuw D, et al. The losartan renal protection study:

rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 2000;1:328-335.

23. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456–1462.

24. Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995;99(5):497–504.

25. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000;36(3):646–661.

26. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345(12):870-878.

27. Schrier RW, Estacio RO, Mehler PS, et al. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial.

Nat Clin Pract Nephrol 2007;3(8):428–438.

28. Strippoli GF, Craig MC, Schena FP, et al. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression.

J Am Soc Nephrol 2006;17(4 Suppl 2):S153–S155.

29. 대한신장학회. 1차 의료기관 의사용 만성콩팥병 예방관리 가이드라인. 2013.

30. USA VA/DoD. VA/DoD clinical practice guideline for the management of chronic kidney disease. 2019.

31. KDIGO. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. 2020.

32. 대한고혈압학회. 2018년 고혈압 진료지침. 2018.

33. Lonn EM, Bosch J, Lopez-Jaramillo P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016;374(21):2009-2020.

34. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.

35. European Society of Cardiology. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021-3104.

36. Lewis JB. Blood pressure control in chronic kidney disease: is less really more?. J Am Soc Nephrol 2010;21(7):1086–1892.

37. Cheung AK, Rahman M, Reboussin DM, et al. Effects of intensive BP control in CKD. J Am Soc Nephrol 2017;28(9):2812-2823.

38. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension.

Cochrane Database Syst Rev 2009;(3):CD004349.

39. Norris K, Bourgoigne J, Gassman J, et al. Cardiovascular outcomes in the African American study of kidney disease and hypertension (AASK) trial. Am J Kidney Dis 2006;48(5):739-751.

40. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288(19):2421-2431.

41. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomized controlled trial. Lancet 2005;365(9463):939-946.

42. 대한의학회·질병관리청. 일차 의료용 근거기반 고혈압 권고 요약본. 2019.

43. Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in

52

of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139(4):244-252.

47. Ruggenenti P, Perna A, Benini R, et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. J Am Soc Nephrol 1999;10(5):997-1006.

48. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). J Hypertens 2013;31(7):1281-1357.

49. KDIGO. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. 2020.

50. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular fltration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349(9069):1857-1863.

51. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insuffciency. N Engl J Med 1996;334(15):939-945.

52. Iino Y, Hayashi M, Kawamura T, et al. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension-a report of the Japanese losartan therapy intended for the global renal protection in hypertensive patients (JLIGHT) study. Hypertens Res 2004;27(1):21-30.

53. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135(2):73-87.

54. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-869.

55. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851-860.

56. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE‐inhibition in non‐diabetic nephropathies with non‐nephrotic proteinuria. Lancet 1999;354(9176):359–364.

57. Cinotti GA, Zucchelli PC. Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non‐diabetic nephropathies. Nephrol Dial Transplant 2001;16(5):961–966.

58. Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006;354(2):131–140.

59. Li PK, Leung CB, Chow KM, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double‐blind, randomized, placebo‐controlled study. Am J Kidney Dis 2006;47(5):751–760.

60. Shoda J, Kanno Y, Suzuki H. A five‐year comparison of the renal protective effects of angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers in patients with non‐diabetic nephropathy. Intern Med 2006;45(4):193–198.

61. Solomon SD, Rice MM, Jablonski KA, et al. Renal function and effectiveness of angiotensin‐converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the prevention of events with ACE inhibition (PEACE) trial. Circulation 2006;114(1):26–31.

62. Tong PC, Ko GTC, Chan WB, et al. The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency. Diabetes Obes Metab 2006;8(3):342–347.

63. Van Hout BA, Simeon GP, McDonnell J, et al. Economic evaluation of benazepril in chronic renal insufficiency. Kidney International 1997;63:S159–S162.

64. Ruggenenti P, Pagano E, Tammuzzo L, et al. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney Int 2001;59(1):286–294.

65. Hogan TJ, Elliott WJ, Seto AH, et al. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation.

Pharmacoeconomics 2002;20(1):37–47.

66. Herman WH, Shahinfar S, Carides GW, et al. Losartan reduces the costs associated with diabetic end‐stage renal disease: the RENAAL study economic evaluation. Diabetes Care 2003;26(3):683–687.

67. Palmer AJ, Annemans L, Roze S, et al. Cost‐effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin‐2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal

54

hypertension management: a European society of hypertension task force document. J Hypertens 2009;27(11):2121-2158.

71. Palmer BF. Managing hyperkalemia caused by inhibitors of the reninangiotensin-aldosterone system. N Engl J Med 2004;351(6):585-592.

72. Bicket DP. Using ACE inhibitors appropriately. Am Fam Physician 2002;66(3):461-468.

73. Sica DA. Diuretic use in renal disease. Nat Rev Nephrol 2011;8(2):100-109.

74. Wilcox CS, Mitch WE, Kelly RA, et al. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med 1983;102(3):450-458.

75. Wilcox C. Diuretics, in Brenner B, Rector F (eds): The Kidney (ed 6). 2000.

76. Sica DA, Gehr TW. Diuretic use in stage 5 chronic kidney disease and end-stage renal disease. Curr Opin Nephrol Hypertens 2003;12(5):483-490.

77. 대한신장학회 CKD 대책위원회·신장학연구재단. 만성콩팥병 진료지침. 2009.

78. 대한의학회·질병관리청. 일차 의료용 근거기반 이상지질혈증 권고 요약본. 2018.

79. ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees.

ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS). Eur Heart J 2011;32(14):1769-1818.

80. KDIGO. KDIGO Clinical practice guideline for lipid management in chronic kidney disease. 2013.

81. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376(9753):1670-1681.

82. KHA-CARI. KHA-CARI guideline: early chronic kidney disease: detection, prevention and management. 2013.

83. ACP. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the American College of Physicians. 2013.

84. Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;157(4):263-275.

85. Upadhyay A, Earley A, Lamont JL, et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;157(4):251-262.

86. 대한신장학회 CKD 대책위원회·신장학연구재단. 만성콩팥병 진료지침.2009.

87. McPherson R, Frohlich J, Fodor G, et al. Canadian cardiovascular society position statement-recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22(11):913-927.

88. KDIGO. KDIGO clinical practice guideline for anemia in chronic kidney disease. 2012.

89. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073–2081.

90. NICE. Chronic kidney disease (partial update): Early identification and management of chronic kidney disease in adults in primary and secondary care (Clinical Guideline 182, Methods, evidence and recommendations). 2014.

91. National Clinical Guideline Centre. Anaemia management in chronic kidney disease:

rapid update 2011. NICE clinical guideline 114. 2011.

92. Stevens PE, O'donoghue DJ, de Lusignan S, et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 2007;72(1):92-99.

93. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084.

94. Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381-388.

95. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-924.

96. KDIGO. KDIGO clinical practice guideline for acute kidney injury. 2012.

97. KDIGO. KDIGO clinical practice guideline for glomerulonephritis. 2012.

98. KDIGO. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).

2017.

99. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: improving global outcomes (KDIGO).

Kidney Int 2011;80:572–586.

100. JSN. Essential points from evidence-based clinical practice guidelines for chronic kidney disease 2018. 2019.

56

Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol 2018;13(3):457-467.

105. O'Lone EL, Hodson EM, Nistor I, et al. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2019;2(2):CD007857.

106. Fukugawa M, Yokoyama K, Koiwa F, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 2013;17(3):247-288.

107. KDOQI Nutrition in CKD Guideline Work Group. KDOQI clinical practice guideline for nutrition in CKD: 2020 update. Am J Kidney Dis 2020;76(3)(suppl 1):S1-S107.